Please Note
We brought you to this page based on your search query. If this isn't what you are looking for, you can continue to Search Results for ""
The maximum number of items you can export is 3,000. Please reduce your list by using the filtering tool to the left.
Close
Você está prestes a deixar o site local do Brasil e será direcionado ao site global. Deseja continuar?
Não exibir esta mensagem novamente
Sim
Não

Voce Buscou por:

You Searched For:

INFORMAÇÕES RELACIONADAS

CONTATOS PRINCIPAIS

PRÓXIMOS EVENTOS

PRODUTOS RELACIONADOS

Produtos Farmacêuticos - Canadá

Destaques

Relatórios
Empresas
Refine sua pesquisa por Segmento de Mercado para obter a Atividade de Rating e Watchlist correspondentes
  DataTipo de Documento Título Emissor/Entidade
26 Apr 2024 Credit Opinion Bausch Health Companies Inc.: Appellate ruling alleviates pressure, but credit profile remains weakly positioned due to untenable capital structure Bausch Health Companies Inc.
22 Apr 2024 Rating Action Moody's Ratings affirms Bausch Health's Caa2 CFR; revises outlook to stable Bausch + Lomb C...
Bausch + Lomb E...
Bausch Health A...
Bausch Health C...
05 Apr 2024 Issuer Profile Bausch Health Companies Inc.: Key facts and statistics - 2023 Bausch Health Companies Inc.
27 Mar 2024 Rating Action Moody's upgrades McKesson's senior unsecured rating to A3, outlook stable California Gold...
General Medical...
McKesson Canada...
McKesson Corpor...
McKesson Financ...
McKesson Financ...
Mckesson Financ...
Mckesson Financ...
Mckesson Financ...
08 Jan 2024 Outlook ESG - Global: 2024 Outlook – Green tech, policy and climate finance to drive credit impact
 The document has been translated in other languages

06 Oct 2023 LGD Assessment Bausch Health Companies Inc. Bausch Health Companies Inc.
27 Sep 2023 Covenant Quality Assessment Bausch + Lomb Escrow Corp.: Covenant Quality Post-Sale Snapshot: $1,400m 8.375% Senior Secured Notes due 2028 Bausch + Lomb C...
Bausch + Lomb E...
Bausch Health C...
13 Sep 2023 Credit Opinion Bausch Health Companies Inc.: Credit profile constrained by generic Xifaxan overhang and pending separation of Bausch + Lomb Bausch Health Companies Inc.
11 Sep 2023 Rating Action Moody's assigns B1 rating to Bausch + Lomb's new secured debt instruments; outlook negative Bausch + Lomb C...
Bausch + Lomb E...
Bausch Health A...
Bausch Health C...
27 Jul 2023 Announcement of Periodic Review Moody's announces completion of a periodic review for a group of Pharmaceutical issuers AbbVie Inc.
Alkermes, Inc.
Alvogen Pharma ...
Amgen Inc.
Amneal Pharmace...
ANI Pharmaceuti...
Azurity Pharmac...
Bausch + Lomb C...
Bausch Health A...
Bausch Health C...
...
Complete Your Profile
Please complete your profile before submitting your comments.
We're Sorry